- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 18.12.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY AND SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER | 2 | HKEx | ||
| 11.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 08.12.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON CT0596 AT ASH 2025 ANNUAL CONGRESS | 1 | HKEx | ||
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.12.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 17.11.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 13.11.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY AND SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER | - | HKEx | ||
| 06.11.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 03.11.25 | CARsgen Therapeutics: CARsgen Announces Positive Clinical Data for Allogeneic CAR-T Products CT0596 and CT1190B | 110 | PR Newswire | SHANGHAI, Nov. 3, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 21.10.25 | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
| 20.10.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS OF SATRI-CEL AT THE ESMO CONGRESS 2025 | 2 | HKEx | ||
| 08.10.25 | CARsgen Therapeutics: CARsgen Presents Results on GPRC5D CAR-T CT071 in The Lancet Haematology | 97 | PR Newswire | SHANGHAI, Oct. 7, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies... ► Artikel lesen | |
| 06.10.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - TO PRESENT UPDATED RESEARCH RESULTS OF CT0596 AT ASH 2025 ANNUAL CONGRESS | 1 | HKEx | ||
| 24.09.25 | CARSGEN-B (02171): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | - | HKEx | ||
| 24.09.25 | CARSGEN-B (02171): PASSING AWAY OF NON-EXECUTIVE DIRECTOR | 1 | HKEx | ||
| 18.09.25 | CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME; AND GRANT OF RSUS PURSUANT TO THE POST-IPO RSU SCHEME | 2 | HKEx | ||
| 18.09.25 | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON ZEVOR-CEL AT 22ND IMS ANNUAL MEETING OF 2025 | - | HKEx | ||
| 04.09.25 | CARSGEN-B (02171): INTERIM REPORT 2025 | 1 | HKEx | ||
| 04.09.25 | CARSGEN-B (02171): TERMS OF REFERENCE FOR THE NOMINATION AND CORPORATE GOVERNANCE COMMITTEE | - | HKEx | ||
| 15.08.25 | CARsgen Therapeutics Holdings reports H1 results | 3 | Seeking Alpha |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MONTE ROSA THERAPEUTICS | 23,280 | +45,50 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects | In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases, demonstrated... ► Artikel lesen | |
| NUVALENT | 106,82 | +9,78 % | Royalty Pharma plc: Royalty Pharma Acquires Royalty Interest in Nuvalent's Neladalkib and Zidesamtinib for Up to $315 Million | NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,730 | +36,62 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,270 | +4,28 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| ERASCA | 5,170 | +43,02 % | Piper Sandler stuft Erasca mit "Overweight" ein - Kursziel bei 5 US-Dollar | ||
| ALUMIS | 17,920 | +10,28 % | Should You Chase the Rally in Alumis Stock Today? | ||
| AVIDITY BIOSCIENCES | 72,37 | +0,21 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 76,69 | +4,41 % | Wolfe Research stuft Kymera Therapeutics wegen fehlender Impulse herab | ||
| RECURSION PHARMACEUTICALS | 4,860 | +6,81 % | JPMorgan Boosts Rating on Recursion Pharmaceuticals (RXRX) Amid AI-Driven Drug Pipeline | ||
| TANGO THERAPEUTICS | 11,790 | +21,92 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Appoints Sung Lee to Board of Directors | ||
| QIAGEN | 40,245 | +0,65 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 292,53 | +7,16 % | Praxis Precision Prices $575 Mln Public Offering At $260/shr | ||
| ADMA BIOLOGICS | 18,820 | +2,62 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| VERA THERAPEUTICS | 48,680 | +4,49 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| DYNE THERAPEUTICS | 19,390 | +7,01 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares | WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven... ► Artikel lesen |
Das Unternehmen CARSGEN THERAPEUTICS HOLDINGS LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.